West Nile Virus Matrix (Intermediate Domain) Blocking Peptide
Référence W155-50
Conditionnement : 50µg
Marque : Leinco Technologies
West Nile Virus Matrix (Intermediate Domain) Blocking Peptide
West Nile Virus Matrix (Intermediate Domain) Blocking Peptide
Product No.: W155
Target West Nile Virus Matrix Protein Product Type Blocking Peptide Alternate Names WNV Matrix Applications IHC FFPE , N , WB |
Antibody DetailsProduct DetailsReactive Species Virus Product Concentration 0.2 mg/ml Amino Acid Location 15 amino acids near the middle of WNV Matrix protein. Formulation This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide. Storage and Handling Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day Ambient Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. Background West Nile Virus Matrix Protein peptide is applicable as a control peptide for blocking antibody binding in Western blotting. Antigen DetailsResearch Area Category B Pathogens . Infectious Disease . Viral . West Nile References & Citations1. Takeda K, Kaisho T, and Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003; 21:335-76. 2. Vogel SN, Fitzgerald KA, and Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 2003; 3:466-77. 3. Janssens S and Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell. 2003; 11:293-302. 4. Sato S, Sugiyama M, Yamamoto M, et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κ B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 2003; 171(8):4304-10. Technical ProtocolsIHC FFPE N |